Vanda Pharmaceuticals Gets FDA Approval for Bipolar, Schizophrenia Treatment
By Kelly Cloonan
Vanda Pharmaceuticals received approval from the Food and Drug Administration for its treatment of a type of bipolar disorder as well as schizophrenia.
The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of schizophrenia in adults.
Vanda expects Bysanti will be commercially available in the third quarter of this year. The company expects that marketing exclusivity for the drug will be protected by regulatory data exclusivity and issued U.S. patents, with the latest expiring in 2044.
Bipolar I disorder affects a significant portion of the roughly 10 million Americans with bipolar disorder, and is characterized by manic or mixed episodes. Schizophrenia affects about 1% of the adult population, or about 2.8 million people, and can cause functional impairment, frequent hospitalizations and diminished quality of life, the company said.
Bysanti is also currently being tested as a once-daily adjunctive treatment in treatment-resistant major depressive disorder in an ongoing clinical study expected to be completed by the end of this year.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
February 20, 2026 18:35 ET (23:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States